Pharmacology and pharmacovigilance of protein kinase inhibitors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Therapies Année : 2022

Pharmacology and pharmacovigilance of protein kinase inhibitors

Résumé

Protein kinase inhibitors experienced their advent in the 2000s. Their market introduction made it possible to constitute a class of targeted therapies administered orally. This name was chosen to mark a break with conventional chemotherapy drugs, but it is important to stress that these are multi-target drugs with complex affinity profiles. Adverse effects can be explained by direct interactions with their targets of interest, chosen for their indications (on-target) but also interactions with other targets (off-target). The adverse effect profiles of these drugs are therefore varied and it is possible to identify common profiles related to inhibitions of common targets. Identification of these targets has improved the global understanding of the pathophysiological mechanisms underlying the onset of adverse drug reactions as well as of the related diseases, and makes it possible to predict the adverse effect profile of new protein kinase inhibitors based on their affinities. In this review, we describe the main adverse drug reactions associated with protein kinase inhibitors, their frequency and their plausible mechanisms of action.
Fichier principal
Vignette du fichier
Khouri et al-2021-Pharmacology and pharmacovigilance of protein kinase inhibitors.pdf (721.71 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03513883 , version 1 (14-01-2022)

Licence

Identifiants

Citer

Charles Khouri, Julien Mahé, Laura Caquelin, Clara Locher, Fabien Despas. Pharmacology and pharmacovigilance of protein kinase inhibitors. Therapies, 2022, 77 (2), pp.207-217. ⟨10.1016/j.therap.2021.11.004⟩. ⟨hal-03513883⟩
100 Consultations
234 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More